Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
BSGI is a molecular breast imaging technique used for the early detectionof breast cancer and in the differentiation of malignant and benign tumors. Itrelies on advanced gamma imaging technology and mammographic positioning tooptimize results. For this study BSGI was conducted with a commerciallyavailable high-resolution gamma camera, the Dilon 6800.
The study evaluated 138 patients with a cancer diagnosis. In this group,additional disease was found in a total of 11 percent of patients. Six percentwere in the same breast and 5 percent were in the opposite breast. Thisfinding is very similar to that of an MRI study conducted by Bilimoria fromNorthwestern University; however, BSGI provided a significantly lower falsepositive rate of 7 percent compared to 78 percent with the MRI study.
Member of the Legacy Good Samaritan Hospital group of surgeons, Dr. M.Zhou, concluded that BSGI parallels MRI in sensitivity in the preoperativesetting, demonstrates better specificity than MRI, and is less expensive thanMRI.
About Dilon Technologies
Dilon Technologies Inc. is bringing innovative new medical imagingproducts to market. Dilon's cornerstone product, the Dilon 6800, is ahigh-resolution, small field-of-view gamma camera, optimized to perform BSGI,a molecular breast imaging procedure which images the metabolic activity ofbreast lesions through radiotracer uptake. Many leading medical centers aroundthe country are now offering BSGI to their patients, including: CornellUniversity Medical Center, New York; George Washington University MedicalCenter, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and TheRose, Houston. For more information on Dilon Technologies please visithttp://www.dilon.com.
M. Zhou MD, N. Johnson MD, S. Gruner MD, G.W. Ecklund MD, P. Meunier MD,S. Bryn RN, G. Green MD. Clinical Utility of Breast Specific Gamma ImagingFor Evaluating Disease Extent in the Newly Diagnosed Breast Cancer Patient.SBAS 18th Annual Scientific Session, Cleveland, OH, April 18, 2008.
SOURCE Dilon Technologies Inc.
You May Also Like